Published May 17, 2018 | Version v1
Patent Open

IL13Ra2 Binding Agents and Use Thereof in Cancer Treatment

  • 1. University of Chicago

Contributors

Patent applicant:

Description

Provided are specific binding molecules, or fragments thereof, that bind to an epitope of IL13Rα2, a receptor polypeptide preferentially found on the surface of cancer cells rather than healthy cells. Exemplary specific binding molecules are bispecific binding molecules that comprise a fragment of an IL13Rα2 binding molecule and a peptide providing a second function providing a signaling function of the signaling domain of a T cell signaling protein, a peptide modulator of T cell activation, or an enzymatic component of a labeling system. Also provided are polynucleotides encoding such a specific binding molecule (e.g., bispecific binding molecule), vectors, host cells, pharmaceutical compositions and methods of preventing, treating or ameliorating a symptom associated with a cancer disease such as a solid tumor disease (e.g., glioblastoma multiforme).

Files

US20180134796.pdf

Files (5.5 MB)

Name Size Download all
md5:eb46ebab8d9ca642666b024383493e57
5.5 MB Preview Download

Additional details

Identifiers

Patent application number
US 201615545945 A
Patent number
US 2018/0134796 A1
Other
oai:uchicago.tind.io:7902

Dates

Patent filed
2016-01-26

UChicago Information

Division(s)
Biological Sciences Division
Department(s)
Neurological Surgery, Medicine